The Clinical Utility and Limitations of Serum Carbohydrate Antigen (CA19-9) as a Diagnostic Tool for Pancreatic Cancer and Cholangiocarcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Koprowski H, Steplewski Z, Mitchell K, et al. Colorectal carcinoma antigen detected by hybridoma antibodies. Somatic Cell Genet. 1979;5:957–972.
Tempero MA, Uchida E, Takasaki H, et al. Relationship of carbohydrate antigen and Lewis antigens in pancreatic cancer. Cancer Res. 1987;47:5501–5503.
Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007;33:266–270.
Steinberg W. The clinical utility of the CA19-9 tumor-associated antigen. Am J Gastroenterol. 1990;85:350–355.
Andriulli A, Gindro T, Plantino P, et al. Prospective evaluation of the diagnostic efficacy of CA19-9 assay as a marker for gastrointestinal cancers. Digestion. 1986;33:26–33.
Uygur-Bayramicli O, Dabak R, Orbay E, et al. Type 2 diabetes mellitus and CA19-9 levels. World J Gastroenterol. 2007;13:5537–5539.
Mertz HR, Sechopoulos P, Delbeke D, et al. EUS, PET, and CT scanning for evaluation of pancreatic adenocarcinoma. Gastrointest Endosc. 2000;52:367–371.
Sreenarasimhaiah J. Efficacy of endoscopic ultrasound in characterizing mass lesions in chronic pancreatitis. J Clin Gastroenterol. 2008;42:81–85.
Mishra G, Conway JD. Endoscopic ultrasound in the evaluation of radiologic abnormalities of the liver and biliary tree. Curr Gastroenterol Rep. 2009;11:150–154.